[PRESS RELEASE] – NEW YORK & HERZLIYA, Israel, Sept. 19, 2025 – InterCure Ltd. introduced the strategic acquisition of Botanico Ltd., often referred to as ISHI, a top rate clinical hashish era and logo corporate that delivers fast get right of entry to to complicated cultivation applied sciences and established partnerships with main American hashish operators.
The purchase comes because the U.S. hashish marketplace stands at a historical doable inflection level, with the Trump management reportedly exploring the rescheduling of hashish from Time table I to Time table III1—a transformative regulatory shift that might free up unheard of alternatives for world hashish corporations reminiscent of InterCure.
ISHI brings an unique partnership with a top-tier indoor facility, subtle AI-driven cultivation optimization programs, automatic manufacturing features, and unique partnerships with top rate U.S. hashish manufacturers, together with established operators like The Flowery, a number one vertically built-in clinical hashish corporate.
The Flowery operates state of the art cultivation and GMP production amenities along the most important supply device in Florida’s clinical marketplace. The Flowery additionally operates the most important retail chain in New York and has a roadmap to proceed its competitive expansion in different U.S. markets.
Thru those partnerships, ISHI has evolved unique get right of entry to to extremely sought-after American genetics, cult manufacturers and confirmed cultivation methodologies that experience established dependable shopper followings throughout more than one U.S. markets. The purchase supplies InterCure with fast get right of entry to to those award-winning genetics, constantly surroundings U.S. high quality requirements, complicated operational applied sciences, and creates really extensive aggressive benefits as the worldwide clinical hashish marketplace an increasing number of calls for pharmaceutical-grade requirements and regulatory frameworks evolve to want established, compliant operators with confirmed world features.
Key Transaction Main points
- Transaction Construction: Two-phase acquisition of 100% of ISHI (Botanico Ltd.) with 50% of the fairness obtained on the preliminary final in attention for two,467,055 InterCure bizarre stocks. The remainder 50% might be obtained upon the sooner of (i) ISHI attaining certain running profitability for no less than 3 consecutive months or (ii) 24 months from the preliminary final, in attention for an extra 2,457,206 InterCure bizarre stocks.
- General Attention: 4,924,261 bizarre stocks of InterCure, representing roughly 10% of InterCure’s exceptional stocks on a completely diluted foundation
- Control Integration: ISHI founders Omer Layani (CEO) and Dor Hershkovitz (leader running officer) sign up for InterCure management group
- Worker Transition: All current ISHI inventory choices convert to InterCure choices, keeping up unique vesting schedules
- Anticipated Ultimate: Q1 2026, matter to regulatory approvals from The Israeli Clinical Hashish Company, The Israel Securities Authority, and The Tel Aviv Inventory Change
- Operational Integration: Fast switch of unique logo partnerships and era platform upon final. The purchase delivers fast get right of entry to to ISHI’s top rate indoor product provide, logo portfolio, era and operational programs that can beef up InterCure’s provide chain and distribution operations whilst supporting growth into world markets the place pharmaceutical-grade requirements are changing into the worldwide benchmark.
“This acquisition represents a vital milestone in our world growth technique,” InterCure CEO Alexander Rabinovich stated. “Via obtaining ISHI, we acquire fast get right of entry to to a couple of The us’s maximum sought-after hashish genetics and confirmed operational applied sciences at precisely the instant once we are inspired by way of the reported fresh momentum within the U.S. round doable hashish rescheduling. This acquisition additionally represents an extra expansion engine for InterCure, and we predict it to turn into accretive to our industry fashion already throughout the first 12 months. As of late, InterCure is uniquely situated to capitalize in this historical doable regulatory shift and ship really extensive price to our shareholders.”
“Becoming a member of InterCure represents the fruits of years construction relationships with The us’s greatest hashish manufacturers,” ISHI CEO Omer Layani stated. “InterCure’s world platform and pharmaceutical-grade requirements give you the absolute best car to scale those partnerships across the world as regulatory tailwinds create unheard of alternatives for strategic partnerships between U.S. and world operators.”
Elad Kohen, founder and CEO of The Flowery, stated, “At The Flowery, our venture is to ship the absolute best expressions of hashish high quality whilst developing cultural reviews that mirror and lift the neighborhood that constructed us. Attaining this calls for companions who proportion our uncompromising requirements for the plant and include a humble, forward-thinking manner. We’ve labored along ISHI for years in this venture and located deep alignment at the ideas that subject maximum. As of late’s announcement strengthens that partnership with higher get right of entry to and assets, empowering us to amplify into new markets the correct way-and proceed rising our neighborhood.”
The transaction stays matter to standard final prerequisites and regulatory approvals.
